Immunotherapy for sepsis using anti-PD-1 and anti-PD-L1 antibodies has shown benefit in animal studies (29–32) while clinical trials in humans have not given the direct benefit evidence of PD-1 or PD-L1 blockade (33, 34). Here, CD274 is linked to Sepsis.